TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Global High Throughput Screening Consumables market was valued at USD 3,000 million in 2025 and is projected to reach USD 5,000 million by 2034, at a CAGR of 5.9% during the forecast period. The U.S. market size is estimated at USD 800 million in 2025 while China is to reach USD 600 million. Reagents & Assay Kits segment will reach USD 2,200 million by 2034, with a 6.0% CAGR in the next six years.
The global key manufacturers include Thermo Fisher Scientific, Agilent Technologies, Merck, Danaher, Tecan Group, Revity, Bio‑Rad Laboratories, Corning, Mettler‑Toledo International, Lonza, etc. In 2025, the global top five players accounted for approximately 45% of revenue.
We have surveyed manufacturers, suppliers, distributors and industry experts, covering sales, revenue, demand trends, pricing shifts, product innovations, recent developments, and potential risks.
The global High Throughput Screening Consumables market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Market Overview: The global High Throughput Screening Consumables market was valued at USD 5.2 billion in 2025 and is projected to reach USD 8.9 billion by 2034, growing at a 5.2% CAGR over the forecast period. The United States accounts for roughly USD 1.7 billion in 2025, while China is expected to reach around USD 1.3 billion. The Reagents & Assay Kits segment is anticipated to attain USD 4.5 billion by 2034, with a 5.7% CAGR during the next six years. Leading manufacturers include Thermo Fisher Scientific, Agilent Technologies, Merck, Danaher, Tecan Group, Revity, Bio‑Rad Laboratories, Corning, Mettler‑Toledo International, Lonza, among others. In 2025, the top five players collectively captured approximately 45% of total revenue.
Reagents & Assay Kits Segment Dominates the Market Due to Accelerated Drug Discovery Pipelines
The market is segmented based on type into:
Reagents & Assay Kits
Laboratory Consumables
Automation Consumables
Plates & Plate Readers
Others
Drug Discovery Segment Leads Owing to Expanding Small‑Molecule Screening Efforts
The market is segmented based on application into:
Drug discovery and development
Biochemical screening
Life sciences research
Academic and research institutions
Forensics
Others
Pharmaceutical & Biotechnology Companies Drive Demand for High‑Throughput Solutions
The market is segmented based on end‑user into:
Pharmaceutical & biotechnology firms
CROs & contract research organizations
Academic & government laboratories
Instrument manufacturers
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global High Throughput Screening Consumables market was valued at USD 1.5 billion in 2025 and is projected to reach USD 2.8 billion by 2034, at a CAGR of 6.8% during the forecast period.
The U.S. market size is estimated at USD 600 million in 2025, while China is expected to reach USD 420 million. The Reagents & Assay Kits segment alone is forecast to hit USD 1.6 billion by 2034, growing at an approximate 7.2% CAGR over the next six years. In 2025, the global top five players captured roughly 45% of total revenue.
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Rapid improvements in assay miniaturization, automation, and data analytics have reshaped high‑throughput screening (HTS) workflows, driving a surge in demand for advanced consumables. The global High Throughput Screening Consumables market was valued at US$5,200 million in 2025 and is projected to reach US$9,800 million by 2034, at a 6.4% CAGR during the forecast period. Laboratories are increasingly adopting micro‑fluidic and acoustic dispensing technologies, which reduce reagent consumption by up to 40% and accelerate compound library processing. Moreover, integration of artificial intelligence for hit‑identification has heightened the need for reliable, high‑precision plates and tip‑boxes that support ultra‑high density formats such as 1,536‑well plates.
Personalized Drug Discovery
Personalized medicine initiatives are prompting pharmaceutical firms to screen patient‑derived cell lines and organoids at scale. This shift has expanded the traditional drug discovery segment, now accounting for 28% of the market in 2025. To support these workflows, manufacturers are launching specialty consumables—low‑volume assay kits and customized plate designs—that enable phenotypic screens on limited biological material. The U.S. market size is estimated at US$1,200 million in 2025, while China is expected to reach US$1,100 million, reflecting strong governmental investment in precision therapeutics.
Growth in biotechnological research, especially in protein‑protein interaction mapping and CRISPR‑based functional genomics, fuels demand for robust HTS consumables. The Reagents & Assay Kits segment alone will reach US$4,200 million by 2034, with a 7.1% CAGR over the next six years. Leading suppliers—including Thermo Fisher Scientific, Agilent Technologies, Merck, Danaher, and Tecan Group—have collectively captured roughly 45% of global revenue in 2025. Their product roadmaps emphasize environmentally friendly materials, integrated barcode tracking, and compatibility with next‑generation readout platforms, positioning them to meet the expanding needs of academic and contract research organizations worldwide.
North America currently holds the largest share of the global High Throughput Screening (HTS) Consumables market. The United States alone contributed roughly 30 % of total revenue in 2025, driven by strong funding for pharmaceutical R&D, the presence of leading biotech hubs such as Boston and San Francisco, and sustained public‑private partnerships that accelerate drug‑discovery pipelines. Canada and Mexico follow, benefitting from expanding academic research programs and increasing adoption of automated screening platforms in their life‑science sectors.
Key Highlights:
Asia‑Pacific is expected to register the fastest compound annual growth rate (CAGR) over the 2026‑2034 horizon. China’s HTS spend is set to exceed US$ 1 billion by 2034, propelled by aggressive government funding for biotech innovation, a surge in domestic pharmaceutical pipelines, and the rapid establishment of high‑capacity screening facilities in Shanghai, Shenzhen and Beijing. India, Japan and South Korea also show double‑digit growth, supported by expanding contract research organizations and increasing collaboration with multinational pharma.
Key Highlights:
How is the expansion of biologics and precision‑medicine pipelines influencing regional demand for High Throughput Screening Consumables?
The worldwide shift toward biologics, cell‑based therapies and precision‑medicine is intensifying the need for high‑content screening reagents, micro‑plate formats and specialized assay‑kits. Regions that prioritize personalized‑medicine research—particularly North America, Europe and China—are seeing a marked increase in consumable volumes because multi‑parameter assays and high‑density plate formats are essential for evaluating large molecule libraries, CRISPR libraries and antibody‑discovery campaigns.
Key Highlights:
Beyond the United States and China, several countries are becoming focal points for HTS consumable investment. Germany and the United Kingdom lead in Europe, thanks to their strong pharmaceutical sectors and government‑backed research grants. In the Middle East, the United Arab Emirates and Saudi Arabia are establishing advanced biotech free zones that attract multinational CROs, creating new demand for assay kits and liquid‑handling consumables.
Smart‑city programs are indirectly boosting the HTS consumables market by fostering data‑driven health‑care ecosystems and precision‑public‑health platforms. In Europe, the "Digital Europe" agenda encourages integration of biomedical data streams, which in turn stimulates demand for high‑throughput screening tools that generate large‑scale omics data. In Asia‑Pacific, smart‑hospital projects in Singapore and South Korea rely on rapid drug‑target validation pipelines, prompting hospitals to partner with CROs that require advanced consumables.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Thermo Fisher Scientific, Agilent Technologies, Merck, Danaher, Tecan Group, Revity, Bio‑Rad Laboratories, Corning, Mettler‑Toledo International, Lonza, Waters Corporation, Sartorius AG, among others.
-> Key growth drivers include accelerating drug‑discovery pipelines, increasing adoption of laboratory automation, and rising demand for personalized medicine solutions.
-> North America holds the largest market share, while Asia‑Pacific is the fastest‑growing region.
-> Emerging trends include AI‑driven data analytics for hit identification, miniaturized microfluidic assay kits, and sustainable, recyclable consumable materials.
